Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 6/20 | 0.51 |
| ▸ | TTK | P33981 | 10/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575646 | 0.91 | MAPKAPK5 (0.48) | MAPKAPK5TTKAURKAFYN | |
| SCHEMBL2068697 | 0.84 | MAPKAPK5 (0.61) | MAPKAPK5TTKAURKAFYN | |
| SCHEMBL5575558 | 0.82 | MAPKAPK5 (0.49) | MAPKAPK5TTKSRCAURKAFYN | |
| SCHEMBL4393746 | 0.81 | MAPKAPK5 (0.72) | MAPKAPK5TTK | |
| SCHEMBL5576245 | 0.81 | TTK (0.54) | MAPKAPK5TTK | |
| SCHEMBL4392693 | 0.77 | MAPKAPK5 (0.68) | MAPKAPK5TTKFYN | |
| SCHEMBL4390569 | 0.76 | MAPKAPK5 (0.58) | MAPKAPK5TTKAURKAFYN | |
| SCHEMBL22122895 | 0.76 | TTK (0.52) | MAPKAPK5TTKSRCAURKA | |
| SCHEMBL5573273 | 0.75 | MAPKAPK5 (0.64) | MAPKAPK5TTKAURKA | |
| SCHEMBL25014253 | 0.75 | TTK (0.56) | MAPKAPK5TTKSRCCSNK2A1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281943-A1 | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | IKZF3, IRAK2, IRAK1 | MAPKAPK5 13/4885TTK 4173/4885SRC 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.